Dominant negative TGFβ receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer
International Immunopharmacology · 2023-11 · 124 · 110807
DOI: 10.1016/j.intimp.2023.110807 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-11. Verfasst von Lei Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Hepatitis A Virus Cellular Receptor 2, Receptor, Transforming Growth Factor-beta Type II, Immunotherapy, Adoptive. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wannan Medical College.
Abstract (Originalsprache)
BACKGROUND: The immune checkpoint molecules, Transforming growth factor beta receptor II (TGFβRII) and T cell immunoglobulin and mucin domain 3 (TIM3), have been identified as contributors to T cell immune suppression in prostate cancer. The objective of this investigation was to improve the tumor killing capability of prostate-specific membrane antigen (PSMA)-chimeric antigen receptor T (CAR-T) cells by targeting TIM3 and TGFβRII simultaneously. METHODS: To generate dnTGFβRII-trTIM3-PSMA-CAR-T (DT-PSMA-CAR-T) cells, the surface of PSMA-CAR-T cells was overexpressed with dominant negative TGFβRII (dnTGFβRII) and truncated extracellular TIM3 (trTIM3). The efficacy of DT-PSMA-CAR-T cells was assessed through in vitro killing experiments and animal experiments. RESULTS: The DT-PSMA-CAR-T cells demonstrated the ability to eradicate PSMA-positive prostate cancer cells, even in the presence of exogenous TGF-β and/or TIM3 activating antibodies. In addition, the cells demonstrated the ability to eliminate tumor tissue in an immunodeficient mouse model transplanted with GAL9-PSMA-PC3 cells in vitro, prolonging survival without significant toxic side effects. CONCLUSIONS: This study emphasizes that upregulating dnTGFβRII and trTIM3 on the surface of T cells can potentially diminish the inhibitory effects of TGFβRII and TIM3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China.
- Department of Center of Precision Medicine, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China.
- Department of Urology, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China. Electronic address: hhb@wnmc.edu.cn.
- Department of Center of Precision Medicine, the First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China. Electronic address: xzy0342102@sina.com.
Förderung
- Wannan Medical College
Zitieren
APA
Tang, L., Shao, H., Wu, Y., Wang, J., Qian, X., He, L., Huang, H., & Xu, Z. (2023). Dominant negative TGFβ receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer. International Immunopharmacology, 124, 110807. https://doi.org/10.1016/j.intimp.2023.110807
Vancouver
Tang L, Shao H, Wu Y, Wang J, Qian X, He L, et al. Dominant negative TGFβ receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer. International Immunopharmacology. 2023;124:110807. doi:10.1016/j.intimp.2023.110807
BibTeX
@article{Tang2023,
author = {Tang, Lei and Shao, Huimin and Wu, Yao and Wang, Jiawei and Qian, Xueyi and He, Lianjun and Huang, Houbao and Xu, Zhenyu},
title = {Dominant negative TGFβ receptor II and truncated TIM3 enhance the antitumor efficacy of CAR-T-cell therapy in prostate cancer},
journal = {International Immunopharmacology},
year = {2023},
volume = {124},
pages = {110807},
doi = {10.1016/j.intimp.2023.110807}
}
EUVIMED